Mounjaro is not FDA-approved for polycystic ovary syndrome (PCOS). Its only approved indication is improving blood sugar control in adults and children 10 and older with type 2 diabetes. However, some doctors prescribe it off-label for PCOS because the drug targets several of the metabolic problems that drive the condition, and early clinical data suggests meaningful benefits.
Why Doctors Prescribe It Off-Label for PCOS
PCOS and insulin resistance are tightly linked. When your body doesn’t respond well to insulin, it compensates by producing more. Those elevated insulin levels then push the ovaries to produce excess androgens (male hormones like testosterone), which cause many of the hallmark symptoms: irregular periods, acne, unwanted hair growth, and difficulty ovulating. Weight gain makes this cycle worse, and losing weight can partially reverse it.
Mounjaro works on two gut hormone pathways simultaneously, making it more effective at lowering blood sugar and promoting weight loss than older medications that target only one. By improving how your body handles insulin and helping with significant weight loss, it can reduce the excess androgen production that fuels PCOS symptoms. Early lab research also suggests these types of medications may directly reduce inflammation in the ovaries and lower androgen levels through pathways beyond just weight loss.
What the Clinical Data Shows So Far
A study published in Fertility and Sterility compared women with PCOS taking metformin alone versus metformin combined with tirzepatide (Mounjaro’s active ingredient). The combination group lost an average of 8.07% of their body weight, compared to just 1.13% in the metformin-only group. Ninety percent of women on the combination achieved weight loss, versus 56.5% on metformin alone. The likelihood of losing weight was nearly twice as high in the combination group.
These are notable numbers for PCOS, where even a 5% to 10% reduction in body weight can restore ovulation and improve hormone levels. The study did not report data on androgen levels or insulin sensitivity specifically, so the full picture of how the combination affects PCOS hormones is still incomplete.
Eli Lilly, the maker of Mounjaro, is now running a dedicated clinical trial called PERIODS (NCT07326111) that tests tirzepatide specifically in women with PCOS who are overweight or obese. The 72-week trial is measuring changes in testosterone, free androgen levels, body weight, and insulin sensitivity. If results are positive, they could eventually support an FDA submission for PCOS as a formal indication.
Mounjaro vs. Zepbound for PCOS
This is a common point of confusion. Mounjaro and Zepbound contain the exact same drug, tirzepatide, but they’re approved for different conditions. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with a BMI of 30 or higher (or 27 or higher with a weight-related condition like high blood pressure or sleep apnea). Neither is approved for PCOS.
If you have PCOS with type 2 diabetes, a doctor could prescribe Mounjaro for the diabetes. If you have PCOS with obesity but no diabetes, Zepbound may be easier to justify from an insurance standpoint since your weight qualifies you for its approved use. The PCOS benefits in either case would be considered a secondary, off-label effect. Coverage varies widely by insurer and plan.
An Important Interaction With Birth Control
Many women with PCOS take oral contraceptives to regulate their cycles and manage androgen levels. Tirzepatide can reduce the effectiveness of birth control pills. The UK’s medicines regulator has issued specific guidance on this: women starting Mounjaro should use a barrier method (like condoms) or switch to a non-oral form of contraception for four weeks after starting the medication and for four weeks after each dose increase. This applies to Zepbound as well, since it’s the same drug. If you’re relying on birth control pills, this interaction is worth discussing before starting treatment.
How It Compares to Metformin
Metformin has been the go-to off-label medication for PCOS for decades. It modestly improves insulin sensitivity and can help with weight, but the effect on weight loss tends to be small. In the comparative study mentioned above, fewer than 60% of women on metformin alone lost any weight at all, and the average loss was just over one pound.
Tirzepatide delivers substantially greater weight loss, which is why interest in it for PCOS is growing. The tradeoff is cost and accessibility. Metformin is generic and inexpensive. Mounjaro carries a list price of over $1,000 per month without insurance, and getting coverage for an off-label use can be difficult. Supply shortages have also been an issue, though availability has improved over time.
What to Expect If You’re Prescribed It
Mounjaro is a once-weekly injection you give yourself with a pen device, typically in the abdomen, thigh, or upper arm. Doctors start at the lowest dose and increase gradually every four weeks to minimize side effects, which most commonly include nausea, diarrhea, decreased appetite, and constipation. These tend to be worst during dose increases and often settle after a few weeks at each level.
For PCOS specifically, the benefits you’d notice first are weight loss and potentially more regular periods, since improved insulin sensitivity and lower body weight can restore ovulation. Changes in androgen-driven symptoms like acne and excess hair growth take longer to become visible, often several months, because those processes respond slowly to hormonal shifts. If you stop the medication, weight regain is common, which can cause PCOS symptoms to return as well.